On this page
- Why this group is different from the joint pages
- What the pooled evidence shows
- The one indication that stands apart
- Other conditions with randomised data
- Immunosuppression is already a treated field
- What an infusion involves
- What this is not
- Risks
- What to ask
- Frequently asked questions
- Requesting a medical evaluation
Autoimmune disease is the most plausible target in this field, because mesenchymal cells demonstrably alter immune behaviour in the laboratory. Stem cell therapy for autoimmune conditions is therefore built on a real mechanism — and a real mechanism is a reason to run trials, not a substitute for having run them.
Why this group is different from the joint pages
In osteoarthritis, the hoped-for action is local: cells injected into a joint influencing the tissue around them. In autoimmune disease it is systemic — infused cells altering how immune cells behave throughout the body.
That is a much bigger claim, and it is also the claim with the clearest laboratory support. Mesenchymal stromal cells suppress T-cell proliferation, shift macrophage behaviour, and release signalling molecules with measurable immune effects in culture.
The distance between a culture dish and a person with lupus is the entire subject of this page. MSC immunomodulation covers what the mechanism research supports and where it stops.
What the pooled evidence shows
The best current summary pools randomised trials across this whole group — Efficacy and safety of mesenchymal stromal cell transplantation in the treatment of autoimmune and rheumatic immune diseases: a systematic review and meta-analysis of randomized controlled trials.
That it exists at all puts autoimmune disease ahead of most of this site. That it pools across very different diseases is also its weakness: lupus, rheumatoid arthritis and inflammatory bowel disease are not one condition, and an average across them describes none of them.
Individual conditions are covered separately here for that reason — lupus, rheumatoid arthritis, Crohn’s disease, ulcerative colitis and multiple sclerosis.
The one indication that stands apart
Perianal fistula in Crohn’s disease has conflicting phase III trial results. The unsuccessful confirmatory trial and EU withdrawal of darvadstrocel must be considered alongside the earlier positive findings.
It is also the least like an infusion. Cells are injected directly into and around the fistula tract during an examination under anaesthetic — a local, surgical, targeted procedure.
When a clinic cites the strength of stem cell evidence in autoimmune disease, this is usually the evidence being pointed at. Ask whether the treatment being offered resembles it in any way.
Other conditions with randomised data
Type 1 diabetes — an autoimmune destruction of insulin-producing cells — has a phase I/II placebo-controlled trial in newly diagnosed patients — Mesenchymal stem cell transplantation in newly diagnosed type-1 diabetes patients: a phase I/II randomized placebo-controlled clinical trial.
Sjögren’s syndrome has a randomised trial of a topical exosome preparation for dry eye — Efficacy of topical mesenchymal stem cell exosome in Sjögren’s syndrome-related dry eye: a randomized clinical trial — which treats a symptom at the eye surface rather than the underlying disease.
Both are narrow, early and specific. Neither supports a general infusion for autoimmune disease, which is what is most commonly sold.
Immunosuppression is already a treated field
Autoimmune disease is not untreated. Biologic drugs have transformed rheumatoid arthritis, inflammatory bowel disease and psoriasis over the last twenty-five years, with large randomised trials and registry data behind them.
Cell therapy is being studied mostly in patients who have failed those drugs. That is the right place to test something new, and it also means the trial populations are unusual — more severe, more refractory, harder to treat.
Results in a refractory population do not transfer to someone newly diagnosed who has not yet tried established treatment. Stopping an effective drug to try an infusion is a decision with real consequences.
What an infusion involves
Intravenous delivery, usually of allogeneic cells from donated umbilical cord tissue, occasionally autologous cells from fat or marrow — umbilical cord MSC therapy covers the difference.
Most infused cells lodge in the lungs on first pass and do not persist long. The proposed action is a short signalling window rather than durable engraftment, which is part of why repeat dosing is common in protocols.
Trial doses are expressed per kilogram of body weight and vary widely — MSC dosage research covers how widely.
What this is not
It is not a bone marrow transplant. Autologous haematopoietic stem cell transplantation genuinely resets the immune system, has serious randomised evidence in some autoimmune conditions, and carries treatment-related mortality. It is a hospital procedure with chemotherapy.
An MSC infusion involves no conditioning chemotherapy, no immune ablation and no reconstitution. The two get deliberately conflated in marketing, and the distinction is the most important one in this whole subject — HSCT versus MSC infusion.
If a clinic’s evidence for an infusion is a transplant trial, that is not their evidence.
Risks
Infusion reactions, fever and transient symptoms are the commonly reported short-term events across trials.
Immunosuppression in someone already immunosuppressed carries infection risk that has to be weighed individually.
Long-term safety data is limited by how recent most of this work is. Documented adverse events covers what has been reported, including from the unregulated sector.
What to ask
- Which specific disease has this been trialled in, and was it mine?
- Were the trial patients refractory to established drugs, and am I?
- What happens to my current medication?
- Is the proposal an infusion, or a targeted local injection like the fistula studies?
The patient journey describes what a proper assessment involves, and what the evidence levels mean explains the grading used across this site.
Frequently asked questions
Is autoimmune disease the best target for stem cell therapy?
It has the most plausible mechanism and a meta-analysis of randomised trials, which is more than most conditions here. Plausible and proven remain different.
Which autoimmune condition has the strongest evidence?
A broad ranking is not a reliable basis for treatment. The Crohn’s fistula programme has conflicting phase III results, and tested a local surgical injection rather than an infusion.
Can I stop my biologic drug?
That is a decision for the specialist managing your disease. Trials in this field were mostly run in patients who had already failed established treatment.
Is this the same as a stem cell transplant for autoimmune disease?
No. Transplant involves chemotherapy and immune ablation in hospital. An infusion involves neither, and the two are routinely conflated.
How many infusions are typical?
Protocols vary widely and are rarely justified from trial data. A lupus trial found two transplants did not outperform one.
Does it work for conditions not listed here?
If a condition has no page here, it is usually because searching the literature returned nothing worth describing.
Requesting a medical evaluation
Nothing on this page establishes whether any treatment is appropriate for you. That needs your history, your imaging and your current medications read by a clinician. If you would like that review, send your records and we will tell you honestly whether there is anything worth discussing — including when the answer is no.
This page is general information, not medical advice, and does not create a doctor–patient relationship. Regenerative treatments discussed here are in most cases investigational. Discuss any treatment with a clinician who knows your history.